# AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

> **NCT07194382** · PHASE2 · RECRUITING · sponsor: **Avalyn Pharma Inc.** · enrollment: 160 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** AP02
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07194382
- **Lead sponsor:** Avalyn Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07194382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07194382, "AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07194382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*